A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects
A Phase 1, First in Human, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Open Label Food Effect Study to Evaluate Safety, Tolerability, and Pharmacokinetics of OR-101 Administered Orally in Healthy Subjects
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Withdrawn
- Declared phase
- Phase 1
- Sponsor
- Ornovi, Inc.
- Participants (registry)
- —
- Start
- October 2023 (planned)
- Primary completion
- February 2024
- Study completion
- February 2024
- Last registry update
- April 2024
- Countries
- Australia
Conditions studied: Alopecia Areata
Interventions: OR-101 (Single ascending dose), OR-101 (Food effect), OR-101 (Multiple ascending dose), Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.